GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Ani Pharmaceuticals Inc. (ANIP) [hlAlert]

Rating:
Buy ANIP
up 11.68 %

Ani Pharmaceuticals Inc. (ANIP) rated Buy with price target $54 by Standpoint Research

Posted on: Friday,  Nov 13, 2015  10:25 AM ET by Standpoint Research

Standpoint Research rated Buy Ani Pharmaceuticals Inc. (NASDAQ: ANIP) on 11/13/2015, when the stock price was $42.95. Since
then, Ani Pharmaceuticals Inc. has gained 11.69% as of 01/05/2016's recent price of $47.97.
If you would have followed this Standpoint Research's recommendation on ANIP, you would have gained 11.68% of your investment in 53 days.

Biosante Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company primary products include gel formulations of testosterone and estradiol. It is also engaged in the development of its calcium phosphate nanotechnology (CaP), primarily for aesthetic medicine, vaccines and drug delivery. The Company?s principal products include LibiGel, Bio-T-Gel and Pill-Plus. The Company?s CaP products in development include BioLook, BioVant, BioOral and BioAir. In October 2009, BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. announced the completion of the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc., with BioSante Pharmaceuticals, Inc. as the surviving company. Pursuant to the merger, BioSante Pharmaceuticals, Inc. has acquired all of the outstanding shares of Cell Genesys, Inc.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/13/2015 10:25 AM Buy
None
42.95 54.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy